Suppr超能文献

第二部分:热熔挤出法制备的尼莫地平固体分散体在比格犬体内的生物利用度

Part II: bioavailability in beagle dogs of nimodipine solid dispersions prepared by hot-melt extrusion.

作者信息

Zheng Xin, Yang Rui, Zhang Yu, Wang Zhijun, Tang Xing, Zheng Liangyuan

机构信息

Department of Pharmaceutics, Shenyang Pharmaceutical University, Shenyang, Liaoning, P.R. China.

出版信息

Drug Dev Ind Pharm. 2007 Jul;33(7):783-9. doi: 10.1080/03639040601050205.

Abstract

The aim of the present work was to investigate the in vitro dissolution properties and oral bioavailability of three solid dispersions of nimodipine. The solid dispersions were compared with pure nimodipine, their physical mixtures, and the marketed drug product Nimotop. Nimodipine solid dispersions were prepared by a hot-melt extrusion process with hydroxypropyl methylcellulose (HPMC, Methocel E5), polyvinylpyrrolidone/vinyl acetate copolymer (PVP/VA, Plasdone S630), and ethyl acrylate, methyl methacrylate polymer (Eudragit EPO). Previous studies of XRPD and DSC data showed that the crystallinity was not observed in hot-melt extrudates, two T(g)s were observed in the 30% and 50% NMD-HPMC samples, indicating phase separation. The weakening and shift of the N-H stretching vibration of the secondary amine groups of nimodipine as determined by FT-IR proved hydrogen bonding between the drug and polymers in the solid dispersion. The dissolution profiles of the three dispersion systems showed that the release was improved compared with the unmanipulated drug. Drug plasma concentrations were determined by HPLC, and pharmacokinetic parameters were calculated after orally administering each preparation containing 60 mg of nimodipine. The mean bioavailability of nimodipine was comparable after administration of the Eudragit EPO solid dispersion and Nimotop, but the HPMC and PVP/VA dispersions exhibited much lower bioavailability. However, the AUC(0-12 hr) values of all three solid dispersions were significantly higher than physical mixtures with the same carriers and nimodipine powder.

摘要

本研究的目的是考察尼莫地平三种固体分散体的体外溶出特性和口服生物利用度。将这些固体分散体与纯尼莫地平、它们的物理混合物以及市售药品尼膜同进行比较。采用热熔挤出工艺,以羟丙基甲基纤维素(HPMC, Methocel E5)、聚乙烯吡咯烷酮/醋酸乙烯酯共聚物(PVP/VA,Plasdone S630)和聚丙烯酸乙酯-甲基丙烯酸甲酯共聚物(Eudragit EPO)制备尼莫地平固体分散体。先前对X射线粉末衍射(XRPD)和差示扫描量热法(DSC)数据的研究表明,在热熔挤出物中未观察到结晶度,在30%和50%尼莫地平-HPMC样品中观察到两个玻璃化转变温度(T(g)),表明发生了相分离。傅里叶变换红外光谱(FT-IR)测定显示,尼莫地平仲胺基团的N-H伸缩振动减弱并发生位移,证明固体分散体中药物与聚合物之间存在氢键。三种分散体系的溶出曲线表明,与未处理的药物相比,其释放得到了改善。通过高效液相色谱法(HPLC)测定药物血浆浓度,并在口服给予每种含60 mg尼莫地平的制剂后计算药代动力学参数。给予Eudragit EPO固体分散体和尼膜同后,尼莫地平的平均生物利用度相当,但HPMC和PVP/VA分散体的生物利用度低得多。然而,所有三种固体分散体的药时曲线下面积(AUC(0-12 hr))值均显著高于与相同载体和尼莫地平粉末的物理混合物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验